IMCHECK THERAPEUTICS
ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
IMCHECK THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Life Science Therapeutics
Founded:
2015-01-01
Address:
Marseille, Provence-Alpes-Cote D'Azur, France
Country:
France
Website Url:
http://www.imchecktherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+33 4 13 96 14 90
Total Funding:
172.93 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Pfizer Venture Investments
Pfizer Venture Investments investment in Series C - ImCheck Therapeutics
Eurazeo
Eurazeo investment in Series C - ImCheck Therapeutics
Life Sciences Partners
Life Sciences Partners investment in Series C - ImCheck Therapeutics
Wellington Partners
Wellington Partners investment in Series C - ImCheck Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series C - ImCheck Therapeutics
Bpifrance
Bpifrance investment in Series C - ImCheck Therapeutics
Pureos Bioventures
Pureos Bioventures investment in Series C - ImCheck Therapeutics
Invus
Invus investment in Series C - ImCheck Therapeutics
Leukemia & Lymphoma Society
Leukemia & Lymphoma Society investment in Series C - ImCheck Therapeutics
Earlybird Venture Capital
Earlybird Venture Capital investment in Series C - ImCheck Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-07-09 | ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer |
Official Site Inspections
http://www.imchecktherapeutics.com Semrush global rank: 8.75 M Semrush visits lastest month: 261
- Host name: vps144.geco-it.net
- IP address: 213.32.33.73
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "ImCheck Therapeutics"
Profile: Imcheck Therapeutics
Since its inception, ImCheck has gained the support of a syndicate of outstanding international funds. The Series C funding, bringing the total capital raised to more than USD 165 million, allows us to advance the clinical validation of First-in …See details»
Imcheck Therapeutics SAS - Drug pipelines, Patents, Clinical
Www.imchecktherapeutics.com. Startups | Holding Company | 2015 | France | 10-50 | www.imchecktherapeutics.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. …See details»
ImCheck Therapeutics - Crunchbase Company Profile …
ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators …See details»
ImCheck Closes Upsized EUR 96 Million (USD 103 ... - Imcheck …
Jun 13, 2022 Series C adds global investors Earlybird, Andera Partners, Invus and patient organization The Leukemia & Lymphoma Society Therapy Acceleration Program ® to the …See details»
ImCheck Therapeutics - LinkedIn
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.See details»
À propos | Work at ImCheck - career.imchecktherapeutics.com
As an organization, we have a responsibility to make Diversity, Inclusion & Equal Opportunity part of our DNA – from integration to supporting our workforce. Our commitment to Diversity, …See details»
ImCheck - EQT Group
Latest news. 29 November 2024 EQT Exeter completes Spanish student housing portfolio sale to Azora; 26 November 2024 EQT portfolio company Parcel2Go announces new ownershipSee details»
ImCheck Therapeutics Company Information - Funding, Investors, …
Get information on funding, investors, industries, and more for ImCheck Therapeutics. See ImCheck Therapeutics company profile and funding data.See details»
ImCheck Therapeutics | Leukemia and Lymphoma Society
Jun 13, 2022 The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. Please check with your …See details»
ImCheck Therapeutics - Craft
ImCheck Therapeutics has 5 employees at their 1 location and $76.08 m in total funding,. See insights on ImCheck Therapeutics including office locations, competitors, revenue, financials, …See details»
Clinical focus - Imcheck Therapeutics
Imcheck Therapeutics : Opening new spaces in Immuno-Oncology. The comprehensive bench-to-bedside research environment offered by the Marseille Cancer Research Center, the Paoli …See details»
Imcheck Therapeutics - Overview, News & Similar companies
Jun 30, 2021 Imcheck Therapeutics contact info: Phone number: +33 413961490 Website: www.imchecktherapeutics.com What does Imcheck Therapeutics do? Founded in 2015 and …See details»
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) …
Marseille, France, June 13, 2022 – ImCheck Therapeutics announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. The Series C …See details»
ImCheck Therapeutics (France) Funding: €172.9M
Nov 7, 2024 ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint...See details»
Home | ImCheck Career
At ImCheck Therapeutics we value the uniqueness of each individual, and helping each person perform to the best of our abilities. We offer a wide number of development opportunities and …See details»
ImCheck Raises $53 Million Series B to Advance Clinical ... - Pfizer
Marseille, France, December 04, 2019, 7:30 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate gamma delta ( ) T cellsin a range of …See details»
ImCheck Therapeutics once again recognized for its potential to …
May 22, 2024 ImCheck is a winner of the French Tech 120 program for the 5th year in a row and a winner of the new French Tech 2030 program announced nearly a year ago.See details»
Press Releases - Imcheck Therapeutics
Nov 5, 2024 ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate …See details»
Pipeline Overview - Imcheck Therapeutics
Imcheck Therapeutics : Opening new spaces in Immuno-Oncology. Pipeline Overview Developing a broad pipeline of novel immunotherapeutic antibodies harnessing the innate & adaptive …See details»